Summary of responses in the combined data set of patients receiving daratumumab 16 mg/kg
| Response . | Patients receiving daratumumab 16 mg/kg (N = 148) . | ||
|---|---|---|---|
| No. . | % . | 95% CI . | |
| ORR | 46 | 31.1 | 23.7-39.2 |
| Clinical benefit (ORR + MR) | 55 | 37.2 | 29.4-45.5 |
| VGPR or better | 20 | 13.5 | 8.5-20.1 |
| CR or better | 7 | 4.7 | 1.9-9.5 |
| sCR | 3 | 2.0 | 0.4-5.8 |
| CR | 4 | 2.7 | 0.7-6.8 |
| VGPR | 13 | 8.8 | 4.8-14.6 |
| PR | 26 | 17.6 | 11.8-24.7 |
| MR | 9 | 6.1 | 2.8-11.2 |
| SD | 68 | 45.9 | 37.7-54.3 |
| PD | 18 | 12.2 | 7.4-18.5 |
| NE | 7 | 4.7 | 1.9-9.5 |
| Response . | Patients receiving daratumumab 16 mg/kg (N = 148) . | ||
|---|---|---|---|
| No. . | % . | 95% CI . | |
| ORR | 46 | 31.1 | 23.7-39.2 |
| Clinical benefit (ORR + MR) | 55 | 37.2 | 29.4-45.5 |
| VGPR or better | 20 | 13.5 | 8.5-20.1 |
| CR or better | 7 | 4.7 | 1.9-9.5 |
| sCR | 3 | 2.0 | 0.4-5.8 |
| CR | 4 | 2.7 | 0.7-6.8 |
| VGPR | 13 | 8.8 | 4.8-14.6 |
| PR | 26 | 17.6 | 11.8-24.7 |
| MR | 9 | 6.1 | 2.8-11.2 |
| SD | 68 | 45.9 | 37.7-54.3 |
| PD | 18 | 12.2 | 7.4-18.5 |
| NE | 7 | 4.7 | 1.9-9.5 |